10x Genomics (TXG) Stock Forecast & Price Target

$20.22

+0.30 (+1.51%)

(As of 07/26/2024 ET)

10x Genomics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold
Based on 14 Analyst Ratings

Based on 14 Wall Street analysts who have issued ratings for 10x Genomics in the last 12 months, the stock has a consensus rating of "Hold." Out of the 14 analysts, 1 has given a sell rating, 7 have given a hold rating, and 6 have given a buy rating for TXG.

Consensus Price Target

$36.29
79.45% Upside

High Forecast	$75.00
Average Forecast	$36.29
Low Forecast	$16.00

According to the 14 analysts' twelve-month price targets for 10x Genomics, the average price target is $36.29. The highest price target for TXG is $75.00, while the lowest price target for TXG is $16.00. The average price target represents a forecasted upside of 79.45% from the current price of $20.22.

Type	Current Forecast 7/27/23 to 7/26/24	1 Month Ago 6/27/23 to 6/26/24	3 Months Ago 4/28/23 to 4/27/24	1 Year Ago 7/27/22 to 7/27/23
Consensus Rating	Hold	Hold	Moderate Buy	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	6 Buy rating(s)	7 Buy rating(s)	8 Buy rating(s)	6 Buy rating(s)
Hold	7 Hold rating(s)	5 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$36.29	$46.62	$60.22	$56.50
Forecasted Upside	79.45% Upside	31.64% Upside	28.32% Upside	25.34% Upside

Get 10x Genomics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for TXG and its competitors with MarketBeat's FREE daily newsletter.

Ad Unstoppable Prosperity

“Generational Bull Run” Incoming

LIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.

You can find out what they are by clicking here now.

TXG Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

TXG Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

10x Genomics Stock vs. The Competition

Type	10x Genomics	Medical Companies	S&P 500
Consensus Rating Score	2.36	2.72	2.50
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	79.45% Upside	3,123.38% Upside	9.16% Upside
News Sentiment Rating	Neutral News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
7/23/2024	Canaccord Genuity Group 1 of 5 stars		Lower Target	Buy ➝ Buy	$50.00 ➝ $32.00	+76.70%
7/22/2024	Jefferies Financial Group 2 of 5 stars		Upgrade	Hold ➝ Buy	$24.00 ➝ $24.00	+43.71%
7/18/2024	Bank of America 4 of 5 stars		Lower Target	Neutral ➝ Neutral	$36.00 ➝ $25.00	+26.01%
7/18/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Overweight ➝ Neutral	$40.00 ➝ $20.00	+0.81%
7/16/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$53.00 ➝ $25.00	+44.34%
7/10/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold	$55.00 ➝ $25.00	+36.99%
Get the Latest News and Ratings for TXG and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for 10x Genomics and its competitors with MarketBeat's FREE daily newsletter.
7/9/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Sell ➝ Sell	$26.00 ➝ $16.00	-10.56%
6/28/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$36.00 ➝ $24.00	+21.33%
6/27/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Schenkel Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Peer Perform
6/25/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Nambi Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
5/1/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$52.00 ➝ $30.00	+11.69%
5/1/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold	$57.00 ➝ $32.00	+9.29%
8/7/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$65.00	+18.20%
8/4/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$65.00 ➝ $75.00	+28.23%
3/30/2023	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight	$65.00	+24.88%
2/16/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$52.00 ➝ $57.00	+23.19%
8/15/2022	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$55.00	+15.59%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 09:30 PM ET.

TXG Forecast - Frequently Asked Questions

What is 10x Genomics' forecast for 2024?: According to the research reports of 14 Wall Street equities research analysts, the average twelve-month stock price forecast for 10x Genomics is $36.29, with a high forecast of $75.00 and a low forecast of $16.00.
Should I buy or sell 10x Genomics stock right now?: 14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for 10x Genomics in the last year. There is currently 1 sell rating, 7 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" TXG shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TXG, but not buy additional shares or sell existing shares.
Does 10x Genomics's stock price have much upside?: According to analysts, 10x Genomics's stock has a predicted upside of 28.44% based on their 12-month stock forecasts.
Has 10x Genomics been upgraded or downgraded by Wall Street analysts recently?: Over the previous 90 days, 10x Genomics's stock had 3 downgrades and 1 upgrade by analysts.
What analysts cover 10x Genomics?: 10x Genomics has been rated by research analysts at Bank of America, Barclays, Canaccord Genuity Group, Deutsche Bank Aktiengesellschaft, Guggenheim, Jefferies Financial Group, JPMorgan Chase & Co., Stifel Nicolaus, TD Cowen, The Goldman Sachs Group, UBS Group, and Wolfe Research in the past 90 days.
Do Wall Street analysts like 10x Genomics more than its competitors?: Analysts like 10x Genomics less than other "medical" companies. The consensus rating for 10x Genomics is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how TXG compares to other companies.